Innate Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Innate Pharma and buy or sell other stocks, ETFs, and their options commission-free!

About IPHA

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. 

CEO
Jonathan Dickinson
CEOJonathan Dickinson
Employees
163
Employees163
Headquarters
Marseille, Provence-Alpes-Cote-dAzur
HeadquartersMarseille, Provence-Alpes-Cote-dAzur
Founded
1999
Founded1999
Employees
163
Employees163

IPHA Key Statistics

Market cap
172.16M
Market cap172.16M
Price-Earnings ratio
-2.90
Price-Earnings ratio-2.90
Dividend yield
Dividend yield
Average volume
4.96K
Average volume4.96K
High today
$1.81
High today$1.81
Low today
$1.79
Low today$1.79
Open price
$1.81
Open price$1.81
Volume
2.44K
Volume2.44K
52 Week high
$2.63
52 Week high$2.63
52 Week low
$1.17
52 Week low$1.17

IPHA News

TipRanks 4d
Innate Pharma Completes Phase 1 Dose Escalation Enrollment for Nectin-4 ADC IPH4502 - TipRanks

...

Innate Pharma Completes Phase 1 Dose Escalation Enrollment for Nectin-4 ADC IPH4502 - TipRanks
TipRanks 4d
Innate Pharma completes enrollment in dose escalation of IPH4502 study

Innate Pharma (IPHA) announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502, its proprietary Nectin-4 exatecan ADC. Preli...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.